[go: up one dir, main page]

WO2014077432A1 - Composition contenant de l'extrait de radix rubiae utilisable pour traiter le cancer du rein et à des fins cosmétiques - Google Patents

Composition contenant de l'extrait de radix rubiae utilisable pour traiter le cancer du rein et à des fins cosmétiques Download PDF

Info

Publication number
WO2014077432A1
WO2014077432A1 PCT/KR2012/009739 KR2012009739W WO2014077432A1 WO 2014077432 A1 WO2014077432 A1 WO 2014077432A1 KR 2012009739 W KR2012009739 W KR 2012009739W WO 2014077432 A1 WO2014077432 A1 WO 2014077432A1
Authority
WO
WIPO (PCT)
Prior art keywords
kidney cancer
extract
composition
cheoncho
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/009739
Other languages
English (en)
Korean (ko)
Inventor
황성연
정경채
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GYEONGSANGBUK-DO MEDICAL CROP CLUSTER
KOREA BIO MEDICAL SCIENCE INSTITUTE Co Ltd
Original Assignee
GYEONGSANGBUK-DO MEDICAL CROP CLUSTER
KOREA BIO MEDICAL SCIENCE INSTITUTE Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GYEONGSANGBUK-DO MEDICAL CROP CLUSTER, KOREA BIO MEDICAL SCIENCE INSTITUTE Co Ltd filed Critical GYEONGSANGBUK-DO MEDICAL CROP CLUSTER
Priority to PCT/KR2012/009739 priority Critical patent/WO2014077432A1/fr
Publication of WO2014077432A1 publication Critical patent/WO2014077432A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to a novel use of cheoncho root extract. Specifically, the present invention relates to a therapeutic composition and a cosmetic composition containing as an active ingredient cheonchogeun extract showing excellent prophylactic or therapeutic efficacy against kidney cancer.
  • the kidney is an important urinary system that has the role of excreting waste products in vitro by filtering blood to produce urine. At the same time, it is also an important endocrine organ that produces hormones such as angiotensin, which regulates blood pressure, and erythropoietin, a red blood cell hematopoietic factor. Renal tumors include kidney cell cancer in adults, Wilms' tumor in children, and sarcoma as a rare tumor, but the most common malignancy below Renal cell cancer, a tumor, is called kidney cancer. The incidence of renal cancer is about 2.5 per 100,000 population, and male to female ratio is 2 to 3: 1. Among urological malignancies, there are many tumors following prostate cancer and bladder cancer.
  • kidney cancer Genetic factors are also known as risk factors for kidney cancer, but generally include smoking and excessive fat intake. It is also known that the incidence of such tumors is high in patients undergoing long-term dialysis. In kidney cancer, when the tumor has a maximum diameter of 5 cm or less, some subjective symptoms rarely occur and are often found by CT scan or the like at the time of examination. Larger tumors may include hematuria, abdominal tumors, and pain. In addition, systemic symptoms may cause fever, weight loss, anemia and the like, and rarely, endocrine factors may cause erythrocytosis, hypertension, hypercalcemia, and the like.
  • vein veins of the abdominal body surface or venous varicose veins occur due to the progression of kidney cancer into the inferior vena cava.
  • About 20% of kidney cancers are found from lung or bone metastases.
  • tumors tend to spread in veins, and metastasis to other organs is likely to occur.
  • VHL von-Hippel-Lindau
  • the main treatment for kidney cancer is surgical therapy. Regardless of the timing of the disease, extraction of the kidneys or partial extraction of the kidneys is the most common where possible, and even if there is metastasis, surgical removal of the kidneys may be considered.
  • Arterial embolization of the renal artery may be used as a method other than the surgical therapy. This method may be performed prior to surgery in cases where it is impossible to extract or when a large tumor is removed.
  • Recent advances in burn diagnostics have led to early detection of renal cancer, even at very small sizes, resulting in more than 90% healing in early cancer. However, since the therapeutic results of large tumors larger than 5 cm or tumors with metastases are poor (the 5-year survival rate of all renal cell carcinomas is about 50 to 60%), the importance of early detection is recognized.
  • Rubiae Radix refers to the same dry roots and rhizomes belonging to Rubiaceae, known as Rubia cordifolia L, Rubia akane Nakai, or Rubia chinensis REGEL. It is a herbal medicine. Cheonchogeun is a lump in shape, the remainder of the stem, there are several or dozens of roots. Conical curved, brown or reddish brown with longitudinal wrinkles. The bark is easily detached and the reddish yellow wood is exposed. The quality is solid, the cross section is reddish and light red and the taste is bitter.
  • Extract levels include vasodilation, shortening blood coagulation time, increased uterine contractility, bladder excitement, lowering blood pressure, dissolving stones, or antibacterial effects.
  • oriental medicine bleeding, hemostasis, and bowing are known. It is known to be applied to blood, carcinoma, etc. (Medicinal Pharmacy, Herbal Medicine School Reorganization Committee, Dongmyeongsa, Seoul, 2000. See Chun Cho Geun). Its ingredients are known as purpurin, alizarin, pseudopurpurin and munjistin. . Tezuka et al., J. Ethnopharmacology, 77, 209-217, 2001 report that various herbal drugs inhibit NO release in in vitro experiments. Meanwhile, U.S. Patent Nos.
  • the present inventors completed the present invention by confirming that the herbal extracts can effectively kill kidney cancer cells during the herbal research on the natural herb.
  • the present invention provides a composition for the prevention and treatment of kidney cancer, comprising the active ingredient extracted with an organic solvent. It is preferable that the said organic solvent is ethanol.
  • the present invention provides a cosmetic composition for preventing kidney cancer containing cheoncho root ethanol extract containing cosmetically acceptable cosmetic supplement additives as an active ingredient.
  • the present invention provides a composition for the prevention and treatment of kidney cancer containing cheoncho root ethanol extract as an active ingredient.
  • the composition of the present invention contains the extract of Cheoncho Geun as an active ingredient, and may further include a pharmaceutically acceptable carrier or diluent.
  • the ethanol extract is preferably extracted at 50 ° C. for 24 hours, wherein the ethanol extract is more preferably dried and concentrated at 45 ° C. under reduced pressure, and the ethanol Is most preferably 95%.
  • the kidney cancer is preferably renal cell cancer.
  • the extraction solution may be obtained by extraction with water or an organic solvent, and examples of the organic solvent may include lower alcohols, acetone, chloroform, methylene chloride, ether, ethyl acetate, and hexane.
  • Lower alcohols include methanol, ethanol, propanol and butanol, with ethanol being most preferred.
  • the extraction process may be repeated two or more times as necessary, and the extract obtained after filtration may be lyophilized or dried under reduced pressure to obtain a powder form.
  • the "pharmaceutically acceptable carrier” is a pharmaceutically acceptable substance such as a liquid or solid filler, diluent, excipient or solvent which serves to transport the active ingredient from one organ or part of the body to another organ or part of the body. , Composition or vehicle.
  • the composition for treating kidney cancer of the present invention may be prepared as a medicament by adding one or more pharmaceutically acceptable carriers together with the active ingredient.
  • the carrier may include, but is not limited to, saline, buffered saline, water, glycerol and ethanol, and any suitable agent known in the art (Remingtons's Pharmaceutical Science (Recent Edition), Mack Publishing Company, Easton PA) may be used. .
  • Formulations for medicating the extract of Cheoncho Geun of the present invention can be administered orally during clinical administration and can be used in the form of general pharmaceutical preparations, and when formulated, commonly used fillers, extenders, binders, wetting agents, disintegrants And diluents such as surfactants or excipients.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc.
  • liquid preparations for oral use include suspensions, solvents, emulsions, and syrups.
  • various excipients may be included, such as wetting sweeteners, fragrances, preservatives and the like.
  • the herbal medicine that may be added to the composition of the present invention may be any pharmaceutically acceptable herbal medicine, for example, Angelica tenuissimae Radix, Gastrodiae Rhizoma, Bapleuri Radix, Angelica ( Angelicae gigantis Radix, Persicae Semen, Cinnamomi Ramulus, Rhubarb (Rhei Rhizoma), Licorice (Glycyrrhizae Radix), Cnidii Rhizoma, Aurantii nobilis Pericarpium, Taxa (Alismatis Rhizoma) Coptidis Rhizoma, Scutellariae Radix, Hoelen, Peeoniae Radix, Atractylodis Rhizoma alba, Phellodendri Cortex, Gardeniae Fructus, Pinelliae Tuber, Ramulu Set (Uncaria) Uncus, Ponciri Fructus, Ginseng, Gingseng, Liriopis Tuber, Poly
  • composition of the present invention may be administered in various parenteral formulations during actual clinical administration, and solid preparations include tablets, pills, powders, granules, capsules, and the like.
  • solid preparations include tablets, pills, powders, granules, capsules, and the like.
  • excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included.
  • preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
  • non-aqueous solvent and the suspension solvent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used.
  • base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • calcium or vitamin D 3 may be added to enhance the efficacy of the treatment.
  • Such compositions may be presented in unit-dose (single) or multi-dose (several) containers, such as sealed ampoules and vials, and immediately before use, sterile liquid carriers such as injectable water. Can be stored under freeze-drying conditions requiring only the addition of. Immediate injection solutions and suspensions can be prepared from sterile powders, granules and tablets.
  • the formulations of the present invention can be applied differently depending on the age, sex, condition of the subject, the absorption of the active ingredient in the body, the inactivation rate and excretion rate, the drug used in combination.
  • the invention also includes formulations of dosage units.
  • the formulations are present in individual dosage forms, such as tablets, coated tablets, capsules, pills, suppositories, and ampoules, wherein the amount of active compound in the drug corresponds to the fraction or multiple of the individual dosage.
  • Dosage units may contain, for example, one, two, three or four times the individual dosage, or 1/2, 1/3 or 1/4 times.
  • the individual dosages preferably contain an amount in which the active compound is administered at one time, which usually corresponds to all, 1/2, 1/3 or 1/4 times the daily dosage.
  • extract refers to an active ingredient isolated from natural products.
  • the extract may be obtained by an extraction process using water, an organic solvent, or a mixed solvent thereof, and includes an extract, a dry powder thereof, or any form formulated using the same.
  • the ethanol extract of Cheoncho-Geun killed 99.4% of ACHN kidney cancer cells at 100 ⁇ g / ml, and the IC 50 (half maximal inhibitory concentration) was 6.7 ⁇ g / ml.
  • the above results demonstrate that the myelin extract of the present invention has excellent killing activity of ACHN renal cancer cells, and further has renal cancer treatment and prophylactic activity.
  • prevention means any action that inhibits or delays the development of kidney cancer by administration of the composition.
  • treatment means any action that improves or advantageously changes the symptoms of kidney cancer by administration of the composition.
  • Cheoncho Geun extract in the present invention can be used to extract using water, an organic solvent, or a mixed solvent thereof. Preferably it is extracted using an organic solvent, in particular ethanol.
  • the extracted solution can be used directly or can be concentrated and / or dried.
  • methanol, ethanol, isopropanol, butanol, ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, dichloromethane, N, N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1,3-butylene glycol, propylene glycol, or a mixed solvent thereof may be used and extracted by room temperature or warming under conditions where the active ingredient of the herbal medicine is not destroyed or minimized.
  • the degree of extraction and loss of the active ingredient of the drug may vary, so select an appropriate organic solvent.
  • the extraction method is not particularly limited, and examples thereof include cold needle extraction, ultrasonic extraction, reflux cooling extraction, and the like.
  • Filtration is a process of removing the suspended solid particles from the extract, it may be used to filter the particles using cotton, nylon or the like, or may be used, such as ultrafiltration, cryofiltration, centrifugal separation, but is not limited thereto.
  • Concentration of the extract may be used, such as concentrated under reduced pressure, reverse osmosis concentration.
  • the drying step after concentration includes freeze drying, vacuum drying, hot air drying, spray drying, reduced pressure drying, foam drying, high frequency drying, infrared drying, and the like. If desired, a process of grinding the final dried extract may be added.
  • the extract can perform an additional fractionation process.
  • the extract is suspended in distilled water to obtain a nonpolar solvent soluble layer by extraction and separation with a nonpolar organic solvent such as hexane, ether, dichloromethane, chloroform, ethyl acetate, or a mixed solvent thereof. It can be used by concentrating and / or drying it.
  • a nonpolar organic solvent such as hexane, ether, dichloromethane, chloroform, ethyl acetate, or a mixed solvent thereof. It can be used by concentrating and / or drying it.
  • the term "pharmaceutically acceptable salts” means salts derived from pharmacologically or physiologically acceptable inorganic acids, organic acids and bases.
  • suitable acid include hydrochloric acid, bromic acid, sulfuric acid, nitric acid, perchloric acid, fumaric acid, maleic acid, phosphoric acid, glycolic acid, lactic acid, salicylic acid, succinic acid, toluene-p-sulfonic acid, tartaric acid, acetic acid, citric acid, methanesulfonic acid, Formic acid, benzoic acid, malonic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid, and the like.
  • Salts derived from suitable bases may include alkali metals such as sodium, alkaline earth metals such as magnesium, ammonium and the like.
  • the pharmaceutical composition for preventing and treating kidney cancer diseases of the present invention comprises 0.1 to 50% by weight of the extract or compound based on the total weight of the composition.
  • the composition does not increase the efficacy, but may include additional ingredients that are commonly used in the pharmaceutical composition to improve the smell, taste, time and the like.
  • the composition adds inorganic and organic additives such as vitamins B1, B2, B6, C, E, niacin, carnitine, betaine, folate pantothenic acid, biotin, zinc, iron, calcium, chromium, magnesium, and mixtures thereof. It can be included as.
  • the composition may include a substance having a therapeutic activity against kidney cancer used alone or used in the past.
  • the term "patient” refers to humans, horses, sheep, pigs, goats, and camels having a disease caused by kidney cancer and its direct and indirect causes, and whose symptoms may be improved by administering the composition of the present invention. Means animals such as nutrition, dogs.
  • a composition comprising the cheoncho root extract of the present invention, it is possible to effectively prevent and treat the above-mentioned kidney cancer.
  • the composition of the present invention can be administered in parallel with existing kidney cancer treatments.
  • the term "administration” means introducing a predetermined substance into a patient by any suitable method, and the route of administration of the composition of the present invention is oral or parenteral via any general route as long as the target tissue can be reached. May be administered.
  • the composition may be administered by any device in which the active agent may migrate to the target cell.
  • composition of the present invention is administered in a pharmaceutically effective amount.
  • pharmaceutically effective amount means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dose level refers to a patient's sexually transmitted disease, age, severity, and drug activity.
  • the compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents and may be administered sequentially or simultaneously with conventional therapeutic agents. It may be single or multiple doses.
  • the method of administering the composition comprising the extract or compound prepared according to the preparation method of the present invention is preferably oral administration or intravenous administration.
  • the effective dose is oral administration, it is usually 1 to 1 time per adult. 500 mg / kg is preferred, and in the case of intravenous administration, 1 to 100 mg / kg is preferred, and may be administered 2-3 times a day.
  • Dosage levels for a particular patient may vary depending on sex, age, lean muscle status, diet, time of administration, method of administration, drug mixture, the condition of the patient and the incidence of neurological disease.
  • the present invention provides a cosmetic composition for preventing kidney cancer, containing the ethanol extract cheoncho root containing an cosmetically acceptable cosmetic supplement additive as an active ingredient.
  • the cosmetic composition of the present invention preferably contains 0.01 to 10% by weight, and more preferably 0.1 to 1% by weight, based on the total weight of the ethanol extract.
  • the cosmetic composition of the present invention is not particularly limited in the formulation, for example, it may have a flexible cosmetic water, nourishing cosmetics, massage cream, nutrition cream, pack, gel or skin adhesive type cosmetic formulation, and also lotion, It may be a transdermal dosage form such as an ointment, gel, cream, patch or spray.
  • the ACHN cells of the present invention were injected into ACHN kidney cancer cells, and it was confirmed that ACHN cells were killed (see FIG. 1 ).
  • the present invention was completed by preparing a cosmetic composition for preventing kidney cancer, containing the extract of Cheoncho root as an active ingredient (see Preparation Example 2 ).
  • the cheoncho root extract of the present invention inhibits the growth of kidney cancer cells and induces apoptosis. Therefore, the composition for treating renal cancer according to the present invention will be very effective in the treatment of renal cancer patients.
  • X-axis is the concentration of cheoncho muscle extract
  • Y-axis is the surviving human kidney The survival rate of cancer cells is shown.
  • Figure 2 shows the results of EdU assay to see if the introduction of the cheoncho muscle obtained in Example 1 in the human kidney cancer cell line ACHN cells to stop the cell cycle and inhibit proliferation of kidney cancer cells.
  • Figure 3 is a reporter assay to determine the effect of the introduction of the cheoncho root obtained in Example 1 on the c-Myc cell signal of kidney cancer cells in ACHN cells, a human kidney cancer cell line, the activity of c-Myc cell signal The result of comparative analysis.
  • Figure 4 is a reporter assay to determine the effect of the introduction of the cheoncho root obtained in Example 1 on the AP-1 cell signal of kidney cancer cells in ACHN cells, a human kidney cancer cell line, the activity of AP-1 cell signal The result of comparative analysis.
  • Example 5 is a reporter assay method for examining the effect of the introduction of the chonchocartilus obtained in Example 1 on the NF- ⁇ B cell signal of kidney cancer cells in ACHN cells, a human kidney cancer cell line. The result of comparative analysis.
  • Figure 6 is a Western blot method to examine the effect of the introduction of the cheoncho muscle obtained in Example 1 in the human kidney cancer cell line ACHN cells to promote the proliferation of kidney cancer cells in the ERK, p-ERK, Ras The results showed that quantitative changes in ⁇ -actin protein were observed.
  • Cheoncho Geun (Chinese) purchased from Seoul Herbal Medicines was dried and ground for 5 days at the shade and room temperature.
  • the ground Cheoncho root was immersed in 30 L of 95% ethanol and extracted at 50 ° C. for 24 hours. This was filtered through filter paper, dried and concentrated under reduced pressure at 45 ° C. to obtain 491 g of the total extract, and stored at ⁇ 20 ° C.
  • ACHN cells which are human kidney cancer cells
  • Alamar Blue assay is a modified form of the MTT assay, in which a specific enzyme degrades a living cell and then measures the fluorescence intensity of the product as the compound breaks down to determine the relative number of living cells after treatment. I am an experimental method. It will be described in more detail below.
  • ACHN cells a kidney cancer cell line used in the present invention, were distributed from Korean Cell Line Bank (KCLB) and used for experiments. Specifically, ACHN kidney cancer cells (Minimum essential medium) containing 10% FBS (fetal bovine serum, fetal bovine serum) (Welgene) and 25 mM HEPES (4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid) Subcultured in medium.
  • FBS fetal bovine serum, fetal bovine serum
  • HEPES 4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid
  • ACHN cells which are kidney cancer cells.
  • ACHN kidney cancer cells were seeded and cultured for 24 hours, and then the Cheoncho root dissolved in dimethyl sulfoxide (DMSO).
  • DMSO dimethyl sulfoxide
  • Table 1 describes the relative cell numbers of kidney cancer cells after 48 hours according to the concentrations of the respective treatments of the kidney muscle cells, based on the number of survival rates of the kidney cancer cells of the control group not treated with the myelin root.
  • the myelin extract of the present invention has excellent ACHN cell killing activity and further demonstrates that it has therapeutic and prophylactic activity for kidney cancer.
  • Cheoncho Geun used in the present invention was widely used as a medicinal herb was determined that there is no problem in the stability, but the oral administration and intraperitoneal toxicity experiments were carried out to confirm this.
  • Acute toxicity test was performed using 6-week-old SPF SD rats. Two animals per group were suspended orally administered at a dose of 5 g / kg in the Cheonchogeun extract of Example 1 of the present invention each suspended in a 0.5% methylcellulose solution. After administration of the test substance, mortality, clinical symptoms, and changes in body weight were observed. Hematological and hematological examinations were performed. Necropsy was performed to observe abdominal and thoracic organ abnormalities.
  • EdU assay is the same test method as BrdU assay and is an improved assay.
  • Halogenated nucleotides such as the pyrimidine analog bromodeoxyuridine (BrdU) are useful for staining DNA in living cells or tissues.
  • phase S which is doubled in the nucleus of the cell cycle and doubled in volume, BrdU is used instead of thymidine in the replicating DNA, and the amount of synthesized DNA can be confirmed by staining with BrdU antibody.
  • the renal cancer cells in culture were treated with C. chondrocytes by concentration, and after 6 hours, EdU was added to the medium and the cells were cultured. After 18 hours, the medium containing EdU was removed and the cells were fixed with 3.7,% paraformaldehyde and washed twice with PBS. After permeation of cells with 0.1% Triton X-100, Alexa Fluor 488 azide was reacted with EdU. Stained with Hoechst 33342 to identify the nuclei of the cells. As shown in Fig. 2, the nucleus of the whole cell is the first one, of which the nuclei of the newly generated cell after the point of treatment of the myopia root are the second one. The third is the sum of these.
  • Reporter gene assay was performed to investigate the effect of S. aureus on the major cell signals that regulate the growth and proliferation of cancer cells.
  • Reporter gene assay is a test technique designed to confirm the change of the cell signal by introducing a reporter gene that can measure the change of a specific cell signal in the cell.
  • the reporter gene designed to measure the cell signal to be confirmed was transfected into cancer cells, stabilized, and the myelin root was treated at each concentration. After 24 hours, the expression level of the reporter gene was compared with 100% of the non-transgenic group and 0% of the non-transduction group.
  • Western blot testing was performed to determine the effect of C. aeruginosa on signaling proteins involved in the major cellular signals that control cancer cell growth and proliferation.
  • Western blot is a test method that separates the whole protein by molecular weight, and then compares the amount of protein to be detected using the antibody of the protein to be identified.
  • the present inventors have confirmed that the cheoncho root extract has excellent renal cancer treatment efficacy through the above examples, and prepared a renal cancer therapeutic agent containing the extract as an active ingredient as follows.
  • the preparation of the following therapeutic agents can be used for the application of not only therapeutic agents but also cosmetic compositions.
  • Cheoncho Geun extract 20% Vitamin C 4.5%, Vitamin D 3 0.001%, Manganese sulfate 0.1%, Beeswax 10%, Palm oil 25%, Safflower seed oil 30.399%
  • the present inventors confirmed that the cheoncho root extract has excellent renal cancer therapeutic activity through the above-described embodiment, and prepared a cosmetic composition containing the same as an active ingredient as follows.
  • the nourishing cream was prepared by a conventional method according to the composition described below.
  • Ointments were prepared in a conventional manner according to the compositions described below.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une utilisation inédite d'un extrait de radix Rubiae, dans le cadre de laquelle une composition utilisable à des fins thérapeutiques et cosmétiques contient, en tant que principe actif, un extrait de radix Rubiae présentant de remarquables effets préventifs et curatifs sur le cancer du rein. L'extrait de radix Rubiae selon la présente invention inhibe le développement des cellules du cancer du rein et induit leur apoptose, si bien qu'il peut être utilisé de façon efficace pour traiter et prévenir le cancer du rein.
PCT/KR2012/009739 2012-11-16 2012-11-16 Composition contenant de l'extrait de radix rubiae utilisable pour traiter le cancer du rein et à des fins cosmétiques Ceased WO2014077432A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/KR2012/009739 WO2014077432A1 (fr) 2012-11-16 2012-11-16 Composition contenant de l'extrait de radix rubiae utilisable pour traiter le cancer du rein et à des fins cosmétiques

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2012/009739 WO2014077432A1 (fr) 2012-11-16 2012-11-16 Composition contenant de l'extrait de radix rubiae utilisable pour traiter le cancer du rein et à des fins cosmétiques

Publications (1)

Publication Number Publication Date
WO2014077432A1 true WO2014077432A1 (fr) 2014-05-22

Family

ID=50731335

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/009739 Ceased WO2014077432A1 (fr) 2012-11-16 2012-11-16 Composition contenant de l'extrait de radix rubiae utilisable pour traiter le cancer du rein et à des fins cosmétiques

Country Status (1)

Country Link
WO (1) WO2014077432A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119405729A (zh) * 2024-12-13 2025-02-11 上海市闵行区中心医院 茜草提取物在制备治疗肿瘤的药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040105902A1 (en) * 2002-12-02 2004-06-03 Jiafang Chen Compositions and methods for treating prostate cancer
KR20120020576A (ko) * 2010-08-30 2012-03-08 주식회사한국전통의학연구소 천초근을 포함하는 전립선암 치료용 조성물
KR20120092280A (ko) * 2011-02-11 2012-08-21 주식회사한국전통의학연구소 천초근 추출물을 포함하는 뇌암 치료용 조성물 및 화장료 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040105902A1 (en) * 2002-12-02 2004-06-03 Jiafang Chen Compositions and methods for treating prostate cancer
KR20120020576A (ko) * 2010-08-30 2012-03-08 주식회사한국전통의학연구소 천초근을 포함하는 전립선암 치료용 조성물
KR20120092280A (ko) * 2011-02-11 2012-08-21 주식회사한국전통의학연구소 천초근 추출물을 포함하는 뇌암 치료용 조성물 및 화장료 조성물

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHOI HO SEUNG ET AL: "INFLUENCE OF RUBIAE RADIX EXTRACT ON THE MECHANISM OF APOPTOSIS IN HL-6", JOURNAL OF PHYSIOLOGY AND PATHALOGY, vol. 22, no. 3, 2008, pages 548 - 555, XP053004746 *
INOUE KATSUHIRO ET AL: "ACTIVITY OF RA-700 A CYCLIC HEXAPEPTIDE FROM RUBIAE RADIX IN HUMAN TUMOR CLONOGENIC ASSAY", INVESTIGATIONAL NEW DRUGS, vol. 4, 1986, pages 231 - 236 *
ITOKAWA HIDEJI ET AL: "PLANT DERIVED NATURAL PRODUCT RESEARCH AIMED AT NEW DRUGS DISCOVERY", JOURNAL OF NATURE MEDICINES, vol. 62, 2008, pages 263 - 280 *
JEONG SU YANG: "STUDIES ON THE ANTICANCER CONSTITUENTS WITH TOPOISOMERASE INHIBITORY ACTIVITY FROM THE ROOTS OF RUBIA CORDIFOLIA L", CATHOLIC UNIVERSITY THESIS, August 2008 (2008-08-01), pages 9-120 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119405729A (zh) * 2024-12-13 2025-02-11 上海市闵行区中心医院 茜草提取物在制备治疗肿瘤的药物中的应用

Similar Documents

Publication Publication Date Title
WO2012134169A2 (fr) Composition pour le traitement du cancer du poumon et aliment fonctionnel contenant un extrait de semence de gleditsiae
KR20120122407A (ko) 석곡 추출물을 포함하는 신장암 치료용 조성물 및 화장료 조성물
WO2012134252A2 (fr) Composition pour le traitement du cancer du rein et aliment fonctionnel contenant un extrait de semence de cannabis
WO2012134250A2 (fr) Composition pour le traitement du cancer du rein et composition pour produits cosmétiques contenant un extrait de rhizome de nardostachys
WO2014077432A1 (fr) Composition contenant de l'extrait de radix rubiae utilisable pour traiter le cancer du rein et à des fins cosmétiques
KR20120122405A (ko) 백축 추출물을 포함하는 신장암 치료용 조성물 및 화장료 조성물
KR20130022724A (ko) 호로파 추출물을 포함하는 신장암 치료용 조성물 및 화장료 조성물
KR20130025336A (ko) 천초근 추출물을 포함하는 췌장암 치료용 조성물 및 화장료 조성물
KR20130023169A (ko) 천초근 추출물을 포함하는 신장암 치료용 조성물 및 화장료 조성물
KR20120111765A (ko) 백두구 추출물을 포함하는 폐암 치료용 조성물 및 화장료 조성물
KR102054437B1 (ko) 조각인 추출물을 포함하는 신장암 치료용 조성물 및 건강 기능성 식품
KR20120092280A (ko) 천초근 추출물을 포함하는 뇌암 치료용 조성물 및 화장료 조성물
WO2012134168A2 (fr) Composition pour le traitement du cancer du poumon et composition pour des produits cosmétiques contenant un extrait d'herbe de lysimachia foenum-graecum
KR20120122409A (ko) 소자 추출물을 포함하는 신장암 치료용 조성물 및 화장료 조성물
WO2014077435A1 (fr) Composition contenant de l'extrait de radix inulae utilisable pour traiter le cancer du rein et à des fins cosmétiques
KR20130027064A (ko) 청피 추출물을 포함하는 신장암 치료용 조성물 및 화장료 조성물
WO2014069695A1 (fr) Composition pour traiter le cancer du pancréas et aliment santé fonctionnel contenant un extrait de boswellia
WO2014069688A1 (fr) Composition pour traiter le cancer rénal et composition cosmétique contenant un extrait de graine de perilla
WO2012134170A2 (fr) Composition pour le traitement du cancer du poumon et composition pour des produits cosmétiques contenant un extrait de racine de rubia
WO2012134251A2 (fr) Composition pour le traitement du cancer du pancréas et composition pour produits cosmétiques contenant un extrait de rhizome de nardostachys
WO2014069692A1 (fr) Composition pour traiter le cancer rénal et aliment santé fonctionnel contenant un extrait d'inula britannica var. chinensis
WO2014069687A1 (fr) Composition pour traiter le cancer rénal et composition cosmétique contenant un extrait de semence de pharbitidis
WO2013147340A1 (fr) Composition et complément alimentaire pour traiter le cancer du poumon, contenant un extrait d'encens
WO2014077433A1 (fr) Composition contenant de l'extrait de semen gleditsiae utilisable pour traiter le cancer du rein et en tant qu'aliment fonctionnel
WO2012134165A2 (fr) Composition pour le traitement du cancer du poumon et composition pour des produits cosmétiques contenant un extrait de semence de psoraleae

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12888363

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12888363

Country of ref document: EP

Kind code of ref document: A1